Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Those who took the drug, which is included in Zepatier (grazoprevir/elbasvir), had a low rate of liver cancer during the following years.
A recent study found that transplanting such kidneys and then treating the recipient for hep C worked well.
Researchers crunched the numbers for transplanting kidneys from donors with hep C and then treating the virus in the recipient.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
Among a group of largely HIV-positive gay and bi men, Zepatier (grazoprevir/elbasvir) boasted a 99 percent cure rate.
Genotype 3 of hepatitis C virus is typically difficult to treat.
More than 125,000 veterans will have received lifesaving cures by October 2018.
With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?
The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.
Zepatier (grazoprevir/elbasvir) is approved to treat those with genotypes 1 and 4 of hepatitis C virus.
Cure rates were near 100 percent even though the population in the study’s analysis had high rates of other health conditions.
A recent analysis of data from a roster of clinical trials yielded reassuring findings for this group of women who have hepatitis C.
A Swiss research program tested for and treated hep C in a large cohort of HIV-positive men who have sex with men over time.
In a recent trial, 12 weeks of the drug combination worked well regardless of whether individuals had drug-resistant virus.
This is according to a recent study of a group of European men who have sex with men who were likely infected sexually.
In a recent small study, those who received such kidneys cured the virus through standard treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.